MedTrace Logo

Perfluorocarbon (ABL-101) Oxygenation for Stroke: Trial With GOLD (Glasgow Oxygen Level Dependent Technology) Imaging Theranostic

NCT03463551 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2018-08-02

No results posted yet for this study

Summary

This study evaluates the safety and tolerability of 3 dose levels of ABL-101 and supplemental oxygen in acute stroke patients.

Conditions

  • Acute Ischaemic Stroke

Interventions

DRUG

ABL-101

ABL-101 is provided as a sterile phospholipid-based emulsion for intravenous administration.

OTHER

0.9% NaCl

Placebo

Sponsors & Collaborators

  • University of Glasgow

    collaborator OTHER

  • Aurum Biosciences Ltd

    collaborator UNKNOWN

  • NHS Greater Glasgow and Clyde

    lead OTHER

Principal Investigators

  • Keith Muir · University of Glasgow

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-30
Primary Completion
2019-09-30
Completion
2020-03-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03463551 on ClinicalTrials.gov